Sponsored Links
| Agennix AG Announces Positive Results With Talactoferrin In Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial In Severe Sepsis |
 |
 |
 |
| Medical News - Cardiovascular and Cardiology | |||
|
Agennix AG (FRANKFURT: AGX) (XETRA: AGX) reported results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo in 190 adult patients with severe sepsis enrolled at 25 leading centers across the U.S... Read more: Cardiovascular / Cardiology News From Medical News Today
|